How does massively parallel DNA sequencing overcome considerations regarding pathological tumor specimens?

How does massively parallel DNA sequencing overcome considerations regarding pathological tumor specimens?

How does massively parallel (or ‘next-generation’) DNA sequencing overcome the following practical considerations regarding pathological tumor specimens? (1) Using FFPE specimens, a process that may damage DNA? (2) Accommodating limited amounts of tissues or extracted DNA available for testing? (3) evaluating specimens in which the relative proportion of tumor nuclei is low?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Jeeyun Lee, MD, PhD

Professor Jeeyun Lee, MD, PhD

Department of Hematology and Oncology
Samsung Medical Center
SungKyunKwan University School of Medicine
Seoul, Korea